Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Combination screen in multi-cell type tumor spheroids reveals interaction between aryl hydrocarbon receptor antagonists and E1 ubiquitin-activating enzyme inhibitor.

Autor: Dexheimer TS; Target Validation and Screening Laboratory, Molecular Pharmacology Laboratory, Applied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, 1050 Boyles Street, Frederick, MD 21702, USA. Electronic address: thomas.dexheimer@nih.gov., Coussens NP; Target Validation and Screening Laboratory, Molecular Pharmacology Laboratory, Applied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, 1050 Boyles Street, Frederick, MD 21702, USA., Silvers T; Target Validation and Screening Laboratory, Molecular Pharmacology Laboratory, Applied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, 1050 Boyles Street, Frederick, MD 21702, USA., Jones EM; Target Validation and Screening Laboratory, Molecular Pharmacology Laboratory, Applied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, 1050 Boyles Street, Frederick, MD 21702, USA., Chen L; Molecular Characterization Laboratory, Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA., Fang J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Morris J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Moscow JA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Teicher BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Publikováno v: SLAS discovery : advancing life sciences R & D [SLAS Discov] 2024 Oct; Vol. 29 (7), pp. 100186. Date of Electronic Publication: 2024 Oct 01.

Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems-based Resource.

Autor: Morris J; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Kunkel MW; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., White SL; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Wishka DG; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Lopez OD; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Bowles L; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Sellers Brady P; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Ramsey P; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Grams J; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Rohrer T; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Martin K; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Dexheimer TS; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Coussens NP; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Evans D; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Risbood P; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Sonkin D; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Williams JD; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Polley EC; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Collins JM; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Teicher BA; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2023 Nov 01; Vol. 22 (11), pp. 1270-1279.

Development of a Cell-Based AlphaLISA Assay for High-Throughput Screening for Small Molecule Proteasome Modulators.

Autor: Staerz SD; Department of Chemistry, Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan 48824, United States., Lisabeth EM; Department of Chemistry, Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan 48824, United States., Njomen E; Department of Chemistry, Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan 48824, United States., Dexheimer TS; Department of Chemistry, Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan 48824, United States., Neubig RR; Department of Chemistry, Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan 48824, United States., Tepe JJ; Department of Chemistry, Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan 48824, United States.

Publikováno v: ACS omega [ACS Omega] 2023 Apr 21; Vol. 8 (17), pp. 15650-15659. Date of Electronic Publication: 2023 Apr 21 (Print Publication: 2023).